Medical Xpress August 7, 2024
Chinese Academy of Sciences

Glioblastoma multiforme (GBM) stands as a formidable adversary in oncology, characterized by its molecular complexity and relentless progression. Despite advancements, the high degree of tumor heterogeneity and its tendency to evade conventional therapies pose significant clinical challenges.

The quest for effective treatments is thus propelled by the necessity to unravel the underlying molecular dynamics and the microenvironment’s role in GBM’s resilience.

Researchers from Hebei University, in a collaborative effort, have unveiled a comprehensive review published in the Cancer Biology & Medicine on May 6, 2024, focusing on the molecular subtyping of GBM and the exploration of its mesenchymal transition mechanisms, which are key to developing targeted therapies.

This pioneering research meticulously dissects the genetic mosaic of glioblastoma, spotlighting the...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Pharma / Biotech, Precision Medicine
Bringing genomics closer to patients: 3 takeaways from Henry Ford Health
Oncologist talks personalized medicine for pancreatic cancer
AI offers a step above genomic solutions
How Mayo Clinic is using real-world data to advance precision medicine
Aignostics Secures $34 Million Series B to Enhance Precision Medicine with AI

Share This Article